<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2017.00103</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gilligan</surname> <given-names>Lorna C.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/403918/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Gondal</surname> <given-names>Ali</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tang</surname> <given-names>Vivien</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hussain</surname> <given-names>Maryam T.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Arvaniti</surname> <given-names>Anastasia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hewitt</surname> <given-names>Anne-Marie</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Foster</surname> <given-names>Paul A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/396648/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Institute of Metabolism and Systems Research, Centre for Endocrinology, Diabetes, and Metabolism, University of Birmingham</institution> <country>Birmingham, UK</country></aff>
<aff id="aff2"><sup>2</sup><institution>Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners</institution> <country>Birmingham, UK</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: <italic>Tea Lanisnik Rizner, University of Ljubljana, Slovenia</italic></p></fn>
<fn fn-type="edited-by"><p>Reviewed by: <italic>Csilla &#x00D6;zvegy-Laczka, Hungarian Academy of Sciences, Hungary; Katja Kristan, Lek Pharmaceuticals, Slovenia</italic></p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x002A;Correspondence: <italic>Paul A. Foster, <email>p.a.foster@bham.ac.uk</email></italic></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>103</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>02</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017 Gilligan, Gondal, Tang, Hussain, Arvaniti, Hewitt and Foster.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Gilligan, Gondal, Tang, Hussain, Arvaniti, Hewitt and Foster</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Hormone replacement therapy (HRT) affects the incidence and potential progression of colorectal cancer (CRC). As HRT primarily consists of estrone sulfate (E<sub>1</sub>S), understanding whether this conjugated estrogen is transported and metabolized in CRC will define its potential effect in this malignancy. Here, we show that a panel of CRC cell lines (Colo205, Caco2, HCT116, HT-29) have steroid sulfatase (STS) activity, and thus can hydrolyze E<sub>1</sub>S. STS activity is significantly higher in CRC cell lysate, suggesting the importance of E<sub>1</sub>S transport in intracellular STS substrate availability. As E<sub>1</sub>S transport is regulated by the expression pattern of certain solute carrier organic anion transporter polypeptides, we show that in CRC OATP4A1 is the most abundantly expressed transporter. All four CRC cell lines rapidly transported E<sub>1</sub>S into cells, with this effect significantly inhibited by the competitive OATP inhibitor BSP. Transient knockdown of OATP4A1 significantly disrupted E<sub>1</sub>S uptake. Examination of estrogen receptor status showed ER&#x03B1; was present in Colo205 and Caco2 cells. None of the cells expressed ER&#x03B2;. Intriguingly, HCT116 and HT29 cells strongly expressed the G protein coupled estrogen receptor (GPER), and that stimulation of this receptor with estradiol (E<sub>2</sub>) and G1, a GPER agonist, significantly (<italic>p</italic> &#x003C; 0.01) increased STS activity. Furthermore, tamoxifen and fulvestrant, known GPER agonist, also increased CRC STS activity, with this effect inhibited by the GPER antagonist G15. These results suggest that CRC can take up and hydrolyze E<sub>1</sub>S, and that subsequent GPER stimulation increases STS activity in a potentially novel positive feedback loop. As elevated STS expression is associated with poor prognosis in CRC, these results suggest HRT, tamoxifen and fulvestrant may negatively impact CRC patient outcomes.</p>
</abstract>
<kwd-group>
<kwd>estrogen</kwd>
<kwd>colorectal cancer</kwd>
<kwd>steroid sulfatase</kwd>
<kwd>OATP</kwd>
<kwd>SLCO</kwd>
<kwd>GPER</kwd>
<kwd>tamoxifen</kwd>
</kwd-group>
<contract-sponsor id="cn001">Society for Endocrinology<named-content content-type="fundref-id">10.13039/501100000382</named-content></contract-sponsor>
<contract-sponsor id="cn002">Medical Research Council<named-content content-type="fundref-id">10.13039/501100000265</named-content></contract-sponsor>
<counts>
<fig-count count="8"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="38"/>
<page-count count="10"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Estrogens play an important role in the etiology of CRC (<xref ref-type="bibr" rid="B8">Foster, 2013</xref>). Pre-menopausal women are protected against CRC compared to age-matched men (<xref ref-type="bibr" rid="B7">Farquhar et al., 2005</xref>), and data from the Women&#x2019;s Health Initiative suggests post-menopausal women on HRT, a combination of estrone sulfate (E<sub>1</sub>S) and progestins, have a 40% reduced incidence of developing CRC compared to women not on HRT (<xref ref-type="bibr" rid="B4">Chlebowski et al., 2004</xref>).</p>
<p>Despite this epidemiological evidence suggesting HRT as protective against CRC, evidence also exists showing estrogens influence CRC proliferation. For example, the CRC cell line Lovo increases proliferation, via a FASN-mediated mechanism, when exposed to estradiol (E<sub>2</sub>) (<xref ref-type="bibr" rid="B31">Santolla et al., 2012</xref>). Indeed, E<sub>2</sub> increases the proliferation of the CRC cell line Caco2 (<xref ref-type="bibr" rid="B6">Di Domenico et al., 1996</xref>) and T84 (<xref ref-type="bibr" rid="B12">Hennessy et al., 2005</xref>), and inhibits apoptosis in DLD-1 cells (<xref ref-type="bibr" rid="B17">Messa et al., 2005</xref>). CRC patients on HRT present at a later and more advanced stage of disease (<xref ref-type="bibr" rid="B4">Chlebowski et al., 2004</xref>), suggesting estrogens as mitogenic in CRC. Thus, the ability of CRC to take up and consequently metabolize E<sub>1</sub>S will define local concentrations of active estrogens and subsequent action.</p>
<p>Steroid sulfatase is the key enzyme involved in hydrolyzing E<sub>1</sub>S to E<sub>1</sub> (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>) (<xref ref-type="bibr" rid="B20">Mueller et al., 2015</xref>), and its activity is known to directly increase the proliferation of estrogen-dependent breast cancer (<xref ref-type="bibr" rid="B10">Foster et al., 2006</xref>) and endometrial cancer (<xref ref-type="bibr" rid="B11">Foster et al., 2008b</xref>). Inhibition of STS has shown significant promise against ER&#x03B1; positive breast cancer (<xref ref-type="bibr" rid="B35">Stanway et al., 2006</xref>; <xref ref-type="bibr" rid="B9">Foster et al., 2008a</xref>). Intriguingly, STS expression, elevated E<sub>1</sub> and E<sub>2</sub> intratumoural concentrations, are associated with a poor prognosis in CRC patients (<xref ref-type="bibr" rid="B32">Sato et al., 2009</xref>). This suggests that colonic estrogen metabolism may play an important role in CRC patient outcomes.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p><bold>Steroid sulfatase activity in CRC cell lines.</bold> E<sub>1</sub>S is transported across the cell membrane by OATPs and once intracellular E<sub>1</sub>S can be hydrolyzed by STS to form E<sub>1</sub>.</p></caption>
<graphic xlink:href="fphar-08-00103-g001.tif"/>
</fig>
<p>However, very little is known about whether E<sub>1</sub>S is transported into CRC. Sulfated steroids require transport into cells via solute carrier organic anion transporting polypeptides (SLCO/OATP); membrane bound proteins that transport a plethora of organic anions (<xref ref-type="bibr" rid="B30">Roth et al., 2012</xref>). Six different SLCO/OATP (OATP1A2, OATP1B1, OATP1B3, OATP2B1, OATP3A1, OATP4A1) are known to effectively transport E<sub>1</sub>S (<xref ref-type="bibr" rid="B20">Mueller et al., 2015</xref>), although their expression and action in CRC is poorly defined. Other OATPs are known to transport E<sub>1</sub>S (OATP4C1 and OATP1C1), however OATP4C1 is primarily expressed in the kidney (<xref ref-type="bibr" rid="B18">Mikkaichi et al., 2004</xref>), and microarray analysis shows it may have some expression in the liver but not the human colon (<xref ref-type="bibr" rid="B1">Bleasby et al., 2006</xref>). OATP1C1 is localized to human brain and testis (<xref ref-type="bibr" rid="B23">Pizzagalli et al., 2002</xref>), and is not evident in human colorectal tissue, as measure by microarray (<xref ref-type="bibr" rid="B1">Bleasby et al., 2006</xref>).</p>
<p>Here, we investigate STS activity and E<sub>1</sub>S transport kinetics in four CRC cell lines. We demonstrate that OATP4A1 is most likely the principle E<sub>1</sub>S transporter in CRC and that all cell lines have the ability to hydrolyze E<sub>1</sub>S. We also show that STS activity in CRC may be regulated by local E<sub>2</sub> availability via a novel GPER mechanism.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Compounds</title>
<p>STX64 (Irosustat, 667COUMATE) was kindly supplied by Prof. Barry Potter (University of Oxford, UK). G1 and G15 were purchased from Torcis Bioscience (Abingdon, UK). E<sub>2</sub>, tamoxifen, fulvestrant, and BSP were purchased from Sigma-Aldrich (Dorset, UK).</p>
</sec>
<sec><title>Cell Culture</title>
<p>The CRC cell lines Colo205, HCT116, and HT29 were purchased from the American Type Culture Collection, USA; Caco2 and JEG3 cells were purchased from The European Collection of Cell Cultures (ECACC). Prior to experiments, all cell lines were authenticated by short tandem repeat profiling and were used between passages 10 and 35. Furthermore, all experiments were performed during the exponential growth phase of the cell line. HCT116 and HT29 were routinely cultured in McCoy&#x2019;s 5a modified medium (Gibco, Life Technologies, USA) with 10% v/v heat inactivated FBS (Sigma-Aldrich, UK). Colo205 cells were culture in RPMI with 10% FBS; Caco2 cells were cultured in MEM with 10% FBS. JEG3 cells were cultured in DM-F12 (Gibco, USA) with 10% FBS. All culture mediums were supplemented with 2 mM <sc>L</sc>-glutamine (Sigma-Aldrich, UK) and 1% PenStrep (Gibco, USA). JEG3 cells were used as control as they exhibit high STS activity.</p>
<p>For experimental conditions, cells were initially starved of estrogens for 72 h by placing them in their appropriate phenol-red free medium plus 10% charcoal stripped FBS (sFBS) (Sigma-Aldrich, UK). After starvation, HCT116 and HT29 cells were treated with E<sub>2</sub> (100 nM), G1 (100 nM), G15 (1 &#x03BC;M), Tamoxifen (10 nM) or fulvestrant (1 &#x03BC;M) in stripped medium for 24 h prior to measuring STS activity.</p>
</sec>
<sec><title>STS Activity Assay</title>
<p><italic>In vitro</italic> STS activities of cell lines were measured as previously described (<xref ref-type="bibr" rid="B26">Purohit et al., 1997</xref>). Briefly, in intact cell assays, cells were incubated with appropriate medium containing [6,7-<sup>3</sup>H] E<sub>1</sub>S (4 &#x00D7; 10<sup>5</sup> dpm, Perkin-ElmerLS, Boston, MA, USA) adjusted to a final concentration of 20 &#x03BC;M with unlabeled E<sub>1</sub>S (Sigma-Aldrich, UK). [4-<sup>14</sup>C] E<sub>1</sub> (1 &#x00D7; 10<sup>4</sup> dpm, Perkin-Elmer) was also included in the reaction mixture to monitor procedural losses. Samples were incubated for 18 h at 37&#x00B0;C after which the product, E<sub>1</sub>, was separated from E<sub>1</sub>S by partition with toluene. A toluene aliquot was removed and <sup>3</sup>H and <sup>14</sup>C radioactivity measured by liquid scintillation spectrometry. The mass of E<sub>1</sub>S hydrolyzed was calculated from the <sup>3</sup>H counts detected corrected for procedural losses. A protein measurement was obtained for the cells by lysing the cells with RIPA buffer (Sigma-Aldrich, UK) followed by a BCA assay (Thermo Fisher Scientific, UK).</p>
<p>To determine STS activity in cell lysates, cells were first lysed with RIPA buffer and protein content determined using a BCA assay. Subsequently, 100 &#x03BC;g of cell protein was incubated for 4 h with PBS containing [6,7-<sup>3</sup>H] E<sub>1</sub>S (4 &#x00D7; 10<sup>5</sup> dpm) adjusted to a final concentration of 20 &#x03BC;M with unlabeled E<sub>1</sub>S. [4-<sup>14</sup>C] E<sub>1</sub> (1 &#x00D7; 10<sup>4</sup> dpm) was again used to monitor procedural losses. E<sub>1</sub> was separated from E<sub>1</sub>S by partition with toluene and <sup>3</sup>H and <sup>14</sup>C radioactivity measured by liquid scintillation spectrometry. Results for both intact and cell lysates were determined as pmol E<sub>1</sub> formed/h/mg protein.</p>
</sec>
<sec><title>qRT-PCR Analysis</title>
<p>From cells mRNA was purified from T75 flasks or six well plates at approximately 80% confluency using RNeasy kits (QIAGEN, Crawley, UK) and stored at -80&#x00B0;C. Aliquots containing 5 &#x03BC;g of mRNA were reverse transcribed in a final volume of 20 &#x03BC;l to form cDNA using Tetro cDNA Synthesis Kit (Bioline Reagents, Ltd, UK). RT-PCR reactions were performed in a &#x2018;Rotor Gene 2000 Real-Time Cycler&#x2019; (Corbett Life Science, Cambridge, UK) with 1 &#x03BC;l cDNA in a final volume of 12 &#x03BC;l, using Taqman universal PCR master mix and Taqman expression assays containing primers and probes for OATP1A2, OATP1B1, OATP1B3, OATP2B1, OATP3A1, OATP4A1, and for the endogenous control gene, RPLP0 (Applied Biosystems, UK). In CRC, RPLPO is considered the most reliable single standard gene to examine (<xref ref-type="bibr" rid="B33">S&#x00F8;rby et al., 2010</xref>). The conditions were as follows: 95&#x00B0;C for 10 min; followed by 40 cycles of 95&#x00B0;C for 15 s, and 60&#x00B0;C for 60 s. Relative mRNA expression was calculated using the comparative quantisation algorithm in the Rotor Gene 6 software (Corbett Life Science).</p>
</sec>
<sec><title>E<sub>1</sub>S Uptake Studies</title>
<p>Cells were seeded at 200,000 cells per well in 6-well plates and allowed to acclimatize for 24 h. Appropriate phenol red free medium containing 10% sFBS plus [6,7-<sup>3</sup>H] E<sub>1</sub>S (4 &#x00D7; 10<sup>5</sup> dpm) was placed on the cells and was subsequently removed after 2, 5, 10, 15, 20, 30 min. For OATP inhibition studies, the competitive OATP inhibitor BSP (at 1 &#x03BC;M) was added to the medium and therefore was present throughout the 30 min uptake time. The cells were then washed twice in PBS, lysed using RIPA buffer, and the intracellular <sup>3</sup>H radioactivity measured by liquid scintillation spectrometry. Cell protein content was also determined with a BCA assay. Results are expressed as E<sub>1</sub>S uptake pmol/mg protein.</p>
</sec>
<sec><title>Immunoblotting</title>
<p>Protein concentration was determined from cell lysates using the BCA assay, and 15 &#x03BC;g samples were separated by electrophoresis under reducing conditions on 4&#x2013;12% Bis-Tris 10% SDS-PAGE gels (Invitrogen, Paisley, UK) before being transferred to PVDF membranes. Membranes were immunoblotted with either ER&#x03B1; (1:1000), ER&#x03B2; (1:1000), GPER (1:800) (all from Santa Cruz, UK), or &#x03B2;-actin (1:50,000) (Sigma-Aldrich, UK) monoclonal antibodies in incubation buffer containing 0.1% milk (Marvel; Premier Brands UK Ltd, Lincolnshire, UK) in TBST. For full details of antibodies and conditions used see <bold>Table <xref ref-type="table" rid="T1">1</xref></bold>. Bound antibody was detected with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies and chemiluminescence detection.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Information regarding antibodies and conditions used for immunoblotting.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Antibody</th>
<th valign="top" align="left">Manufacturer, Cat. #, Lot #</th>
<th valign="top" align="left">Peptide/protein target</th>
<th valign="top" align="left">Species raised, monoclonal/polyclonal</th>
<th valign="top" align="left">Dilution used</th>
<th valign="top" align="center">Positive control</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">ER&#x03B1;</td>
<td valign="top" align="left">Santa Cruz, sc-130072, C2910</td>
<td valign="top" align="left">aa 301&#x2013;595</td>
<td valign="top" align="left">Mouse, monoclonal</td>
<td valign="top" align="left">1:1000, 1% milk</td>
<td valign="top" align="center">MCF-7</td>
</tr>
<tr>
<td valign="top" align="left">ER&#x03B2;</td>
<td valign="top" align="left">Abcam, ab288, GR79420-5</td>
<td valign="top" align="left">aa 1&#x2013;153</td>
<td valign="top" align="left">Mouse, monoclonal</td>
<td valign="top" align="left">1:1000, 1% milk</td>
<td valign="top" align="center">MCF-7</td>
</tr>
<tr>
<td valign="top" align="left">GPER</td>
<td valign="top" align="left">Santa Cruz, sc-48525-R, F2414</td>
<td valign="top" align="left">N-terminus</td>
<td valign="top" align="left">Rabbit, Polyclonal</td>
<td valign="top" align="left">1:800, 5% milk</td>
<td valign="top" align="center">MCF-7</td>
</tr>
<tr>
<td valign="top" align="left">&#x03B2;-actin</td>
<td valign="top" align="left">Sigma, A228</td>
<td valign="top" align="left">slightly modified &#x03B2;-cytoplasmic actin N-terminal peptide</td>
<td valign="top" align="left">Mouse, Monoclonal</td>
<td valign="top" align="left">1:50,000</td>
<td valign="top" align="center"></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec><title>siRNA Transfection</title>
<p>Twenty four hours after seeding HCT116 cultures were transfected with OATP-specific and control siRNA (Thermo Fisher Scientific, UK) by lipofectamine-2000 (Invitrogen) using standard protocols. 72 h post-transfection, E<sub>1</sub>S uptake studies were performed over 30 min and total E<sub>1</sub>S uptake calculated.</p>
</sec>
</sec>
<sec><title>Results</title>
<sec><title>STS Activity in Intact and Lysed CRC Cell Lines</title>
<p>The panel of four CRC cell lines, plus the positive control JEG3, were investigated and demonstrate a wide range of STS activity (<bold>Figures <xref ref-type="fig" rid="F2">2A,B</xref></bold>). In intact (not lysed) cells, Caco2 exhibited the highest STS activity (65.47 &#x00B1; 28.51 pmol/mg/h), with HCT116 cells having the lowest activity (1.65 &#x00B1; 0.14 pmol/mg/h). STS activity could be almost completely inhibited in intact cells using 1 &#x03BC;M of the specific STS inhibitor STX64 (<bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p><bold>(A)</bold> Steroid sulfatase activity (E<sub>1</sub>S conversion in pmol/mg/h) and inhibition by STX64 (1 &#x03BC;M) in intact CRC cell lines. <bold>(B)</bold> STS activity and inhibition by STX64 (1 &#x03BC;M) in CRC cell lysate. JEG3 cells were used as a positive control in all experiments. Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments.</p></caption>
<graphic xlink:href="fphar-08-00103-g002.tif"/>
</fig>
<p>When lysed, the intracellular STS activity was much greater in all cell lines examined compared to their intact state (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>). STS activity was again greatest in the Caco2 cell lines (452.90 &#x00B1; 56.34 pmol/mg/h) with HCT116 cell showing the lowest STS activity (11.87 &#x00B1; 6.41 pmol/mg/h). These results demonstrate that E<sub>1</sub>S uptake kinetics most likely dictate the ability of CRC to hydrolyze E<sub>1</sub>. Therefore, as E<sub>1</sub>S is transported through the cell membrane by OATPs the expression of these transporters was next determined.</p>
</sec>
<sec><title>OATP Expression and E<sub>1</sub>S Uptake in CRC Cell Lines</title>
<p>The mRNA expression of OATPs known to transport E<sub>1</sub>S across the plasma membrane was determined in the panel of CRC cell lines (<bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). Of the six OATPs examined only OATP4A1 was present in all four cell lines. OATP2B1 expression was also notably high in Caco2 cells. The HT29 cells expressed five of the six OATPs determined (OATP1B3 was not present in HT29 cells), with the Caco2 cells expressing four (OATP1A1, OATP1B3, OATP2B1, OATP4A1) out of six. Our results are roughly consistent with the expression patterns obtained from the CellMiner database<sup><xref ref-type="fn" rid="fn01">1</xref></sup>, as shown by average transcript log<sup>2</sup> intensities (see <bold>Table <xref ref-type="table" rid="T2">2</xref></bold>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p><bold>Organic anion transporter polypeptide mRNA expression in Colo205, Caco2, HCT116, and HT-29 cells.</bold> OATP4A1 expression was the highest in all cell lines. Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments.</p></caption>
<graphic xlink:href="fphar-08-00103-g003.tif"/>
</fig>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Average transcript log<sup>2</sup> intensities determined from the National Cancer Institute (NCI) CellMiner database (<ext-link ext-link-type="uri" xlink:href="https://discover.nci.nih.gov/cellminer/">https://discover.nci.nih.gov/cellminer/</ext-link>).</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left"></td>
<th valign="top" align="left">1A2</th>
<th valign="top" align="left">1B1</th>
<th valign="top" align="left">1B3</th>
<th valign="top" align="left">2B1</th>
<th valign="top" align="left">3A1</th>
<th valign="top" align="left">4A1</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Colo205</td>
<td valign="top" align="left">3.24</td>
<td valign="top" align="left">3.22</td>
<td valign="top" align="left">5.50</td>
<td valign="top" align="left">7.29</td>
<td valign="top" align="left">4.76</td>
<td valign="top" align="left">8.38</td>
</tr>
<tr>
<td valign="top" align="left">HCT116</td>
<td valign="top" align="left">2.96</td>
<td valign="top" align="left">3.23</td>
<td valign="top" align="left">5.75</td>
<td valign="top" align="left">5.34</td>
<td valign="top" align="left">4.61</td>
<td valign="top" align="left">8.19</td></tr>
<tr>
<td valign="top" align="left">HT29</td>
<td valign="top" align="left">2.84</td>
<td valign="top" align="left">2.89</td>
<td valign="top" align="left">4.92</td>
<td valign="top" align="left">5.39</td>
<td valign="top" align="left">6.54</td>
<td valign="top" align="left">8.04</td></tr>
</tbody></table>
<table-wrap-foot>
<attrib><italic>Average log<sup>2</sup> determined from mRNA various probes/probe sets.</italic></attrib>
</table-wrap-foot>
</table-wrap>
<p>When the ability of CRC cells to transport E<sub>1</sub>S into the cells was determined, Colo205 demonstrated the quickest uptake rate, with HCT116 cells having the slowest uptake (<bold>Figure <xref ref-type="fig" rid="F4">4A</xref></bold>). Inhibition of OATP transport with the non-specific OATP inhibitor BSP significantly reduced E<sub>1</sub>S uptake in all four cell lines (<bold>Figures <xref ref-type="fig" rid="F4">4B&#x2013;E</xref></bold>). Caco2 cells had the most rapid with HCT116 cells exhibited the slowest E<sub>1</sub>S transport. E<sub>1</sub>S uptake after 30 min demonstrated that Colo205 (89.41 &#x00B1; 16.80 pmol/mg) and Caco2 (61.78 &#x00B1; 10.80 pmol/mg) cells exhibited the most intracellular E<sub>1</sub>S transport, with HCT116 (16.73 &#x00B1; 6.80 pmol/mg) and HT29 (34.59 &#x00B1; 5.63 pmol/mg) cells showing lower E<sub>1</sub>S transport (<bold>Figure <xref ref-type="fig" rid="F4">4F</xref></bold>). BSP significantly (<italic>p</italic> &#x003C; 0.001) inhibited E<sub>1</sub>S transport in all four cell lines.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p><bold>Estrone sulfate transport in Colo205, Caco2, HCT116 and HT-29 cells. (A)</bold> Comparison of the different uptake kinetics of E<sub>1</sub>S over 30 min in four CRC cell lines. <bold>(B)</bold> Inhibition of Colo205 E<sub>1</sub>S transport by BSP (1 mM). <bold>(C)</bold> Inhibition of Caco2 E<sub>1</sub>S transport by BSP. <bold>(D)</bold> Inhibition of HCT116 E<sub>1</sub>S transport by BSP. <bold>(E)</bold> Inhibition of HT-29 E<sub>1</sub>S transport by BSP. <bold>(F)</bold> Total E<sub>1</sub>S uptake over 30 min by four CRC cell lines and the total inhibition caused by BSP. Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments. <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.001 compared to control.</p></caption>
<graphic xlink:href="fphar-08-00103-g004.tif"/>
</fig>
<p>To examine if OATP inhibition by BSP reduces E<sub>1</sub>S intracellular substrate availability to STS, we examined the effect of BSP on STS activity in intact cells and cell lysates. We selected Caco2 and HCT116 cells as representative of CRC cells with high and low STS activity, respectively. In intact cells, treatment with BPS (1 &#x03BC;M) non-significantly reduced STS activity in Caco2 cells but had no effect on HCT116 STS activity (<bold>Figure <xref ref-type="fig" rid="F5">5A</xref></bold>). When BPS (1 &#x03BC;M) was tested in cell lysates it had no effect on STS activity in both Caco2 and HCT116 cells, suggesting it does not directly inhibit the STS enzyme (<bold>Figure <xref ref-type="fig" rid="F5">5B</xref></bold>). These results imply that OATP transport into cells plays a rate-limiting step on E<sub>1</sub>S STS hydrolysis. The discrepancy between Caco2 and HCT116 cells in response to BSP most likely represents the difference between the STS activity in the cell lines. When STS activity is high (Caco2), limiting E<sub>1</sub>S OATP transport limits intracellular E<sub>1</sub>S availability thus reducing E<sub>1</sub> hydrolysis. When STS activity is low (HCT116), limiting E<sub>1</sub>S OATP transport does not directly translate to decreased hydrolysis as there is less STS activity, and thus limiting substrate availability via OATP inhibition and where enzyme activity is already low does not translate to reduced E<sub>1</sub>S hydrolysis.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p><bold>Bromsulfthalein has limited effect on STS activity Caco2 and HCT116 cells. (A)</bold> In intact cells, STS activity is non-significantly reduced by BSP (1 &#x03BC;M) in Caco2 cells and has no effect on HCT116 cells. <bold>(B)</bold> In cell lysates, BSP (1 &#x03BC;M) has no effect on STS activity in Caco2 or HCT116 lysates. Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments.</p></caption>
<graphic xlink:href="fphar-08-00103-g005.tif"/>
</fig>
<p>As OATP2B1 and OATP4A1 were expressed at the highest concentrations compared to the other OATPs, we next performed siRNA knockdown of these two transporters in HCT116 cells to determine their importance on E<sub>1</sub>S uptake. We used HCT116 cells as they had high OATP2B1 and OATP4A1 expression without high expression of any other OATPs. Furthermore, HCT116 cells are readily transfected by lipofectamine for siRNA delivery. For both OATPs siRNA gave &#x003C; 95% knockdown as measured by qRT-PCR (<bold>Figure <xref ref-type="fig" rid="F6">6A</xref></bold>). OATP2B1 knockdown did not significantly affect E<sub>1</sub>S uptake (<bold>Figure <xref ref-type="fig" rid="F6">6B</xref></bold>), however OATP4A1 knockdown significantly reduced E<sub>1</sub>S uptake from 21.02 &#x00B1; 3.12 to 8.93 &#x00B1; 2.07 pmol/mg/h (<italic>p</italic> &#x003C; 0.01), suggesting this transporter may play a key role in E<sub>1</sub>S transport in CRC.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p><bold>OATP4A1 knockdown in HCT116 cells blocks E<sub>1</sub>S transport. (A)</bold> siRNA knockdown of OATP2B1 and OATP4A1 reduced transporter expression by over 95%. <bold>(B)</bold> In HCT116 cells OATP2B1 knockdown has no effect on E<sub>1</sub>S transport, however OATP4A1 knockdown inhibited E<sub>1</sub>S transport by 52.4%. Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments. <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01 compared to control.</p></caption>
<graphic xlink:href="fphar-08-00103-g006.tif"/>
</fig>
</sec>
<sec><title>STS Activity is Regulated by E<sub>2</sub> Availability and GPER Action in CRC</title>
<p>As steroid metabolism and estrogen action in the colon is poorly defined we next speculated whether estrogens may influence steroid sulfatase activity, as it has been reported to do in other malignancies (<xref ref-type="bibr" rid="B38">Zaichuk et al., 2007</xref>). Thus we next examined how E<sub>2</sub> starvation and subsequent E<sub>2</sub> supplementation effects STS activity. HT29 cell treated with sFBS medium (i.e., estrogen starvation) demonstrated a trend toward reduction in STS activity, with this effect reversed when supplemented with E<sub>2</sub> (<bold>Figure <xref ref-type="fig" rid="F7">7A</xref></bold>). In HCT116 cells, 24 h of E<sub>2</sub> (100 nM) treatment significantly (<italic>p</italic> &#x003C; 0.01) induced STS activity compared to sFBS controls (<bold>Figure <xref ref-type="fig" rid="F7">7B</xref></bold>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption><p><bold>Steroid sulfatase activity is regulated by estrogen availability in CRC cell lines. (A)</bold> E<sub>2</sub> (100 nM) does not increase STS activity in HT29. <bold>(B)</bold> E<sub>2</sub> (100 nM) significantly increase STS activity in HCT116 cells. <bold>(C)</bold> 24 h treatment of Tamoxifen (10 nM) and fulvestrant (1 mM) increases STS activity in HCT116 cells. <bold>(D)</bold> Colo205 and Caco2 cells express ER&#x03B1;, but not ER&#x03B2;. HCT116 and HT29 cells do not express ER&#x03B1; or ER&#x03B2;. The +ive control is MCF-7 protein. <bold>(E)</bold> GPER is expressed in HCT116 and HT29 cells. Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments. <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01 compared to sFBS control.</p></caption>
<graphic xlink:href="fphar-08-00103-g007.tif"/>
</fig>
<p>We next attempted to inhibit this E<sub>2</sub>-induced increase in STS activity by treating HCT116 with Tamoxifen or fulvestrant co-administered with E<sub>2</sub>. Surprisingly, both Tamoxifen and fulvestrant significantly increased STS activity in HCT116 cells (<bold>Figure <xref ref-type="fig" rid="F7">7C</xref></bold>) and neither compound had any effect on E<sub>2</sub>-induced STS activity. Tamoxifen (at 10 nM) increased STS activity to 6.43 &#x00B1; 0.95 pmol/mg/h and fulvestrant (1 &#x03BC;M) increase activity to 7.84 &#x00B1; 1.36 pmol/mg/h compared to 2.43 &#x00B1; 0.31 pmol/mg/h.</p>
<p>Examination of the CRC cell lines ER status demonstrated that ER&#x03B1; protein expression was present in Caco2 cells, and lowly expressed in Colo205 cells. HCT116 and HT29 cells did not express ER&#x03B1; (<bold>Figure <xref ref-type="fig" rid="F7">7D</xref></bold>). None of the cell lines expressed ER&#x03B2; (<bold>Figure <xref ref-type="fig" rid="F7">7D</xref></bold>). We also assessed the GPER status in our CRC cell lines. HCT116 and HT29 cells expressed GPER (<bold>Figure <xref ref-type="fig" rid="F7">7E</xref></bold>), as did Caco2 and Colo205 (data not shown). Unedited immunoblots are shown in Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">1</xref>. As both Tamoxifen and fulvastrant have been shown to be GPER agonist (<xref ref-type="bibr" rid="B25">Prossnitz and Barton, 2014</xref>) we next examined whether the increased STS activity induced by these compounds could be inhibited by G15, a specific GPER antagonist (<xref ref-type="bibr" rid="B5">Dennis et al., 2009</xref>). In HCT116 cells, G15 (1 &#x03BC;M) significantly inhibited the increase of STS activity induced by 24 h treatment with E<sub>2</sub> (100 nM), the GPER agonist G1 (100 nM), Tamoxifen (10 nM), and fulvestrant (1 &#x03BC;M) (<bold>Figure <xref ref-type="fig" rid="F8">8</xref></bold>). This suggests a potential novel positive estrogen metabolism feedback loop through GPER stimulation is present in CRC.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption><p><bold>Stimulation of GPER increases STS activity in HCT116 cells.</bold> E<sub>2</sub> (100 nM), G1 (100 nM), Tamoxifen (10 nM), and fulvestrant (1 mM) induce increased STS activity in HCT116 cells. These effects are inhibited by the addition of the GPER antagonist G15 (1 mM). Data represents mean &#x00B1; SD. <italic>n</italic> = 3 independent experiments. <sup>&#x2217;</sup><italic>p</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &#x003C; 0.01.</p></caption>
<graphic xlink:href="fphar-08-00103-g008.tif"/>
</fig>
</sec>
</sec>
<sec><title>Discussion</title>
<p>Hormone replacement therapy, usually a combination of equine E<sub>1</sub>S and progestins, may play a dual role in the incidence and progression of CRC. Initially protective against the development of CRC (<xref ref-type="bibr" rid="B4">Chlebowski et al., 2004</xref>), once the malignancy is formed CRC may be estrogen responsive (<xref ref-type="bibr" rid="B8">Foster, 2013</xref>). Thus, defining how CRC transports and metabolizes estrogens, and the ER status of CRC, may define how this tissue responds to HRT. Here we demonstrate that CRC cell lines possess STS activity (see <bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>) and are able to transport E<sub>1</sub>S (see <bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>), most likely through OATP4A1 (see <bold>Figure <xref ref-type="fig" rid="F6">6</xref></bold>), into cells. Furthermore, we show that STS activity is elevated by local E<sub>2</sub> concentrations (see <bold>Figure <xref ref-type="fig" rid="F7">7</xref></bold>) via GPER action. Finally we show that tamoxifen and fulvestrant, both GPER agonists, also elevate STS activity (see <bold>Figure <xref ref-type="fig" rid="F8">8</xref></bold>) indicating that its use in breast cancer patients may have unwanted consequences in the colon.</p>
<p>Elevated STS expression has been demonstrated in breast (<xref ref-type="bibr" rid="B22">Pasqualini et al., 1996</xref>), prostate (<xref ref-type="bibr" rid="B21">Nakamura et al., 2006</xref>) endometrial (<xref ref-type="bibr" rid="B15">Lepine et al., 2010</xref>), and epithelial ovarian cancer (<xref ref-type="bibr" rid="B29">Ren et al., 2015</xref>). We demonstrate here for the first time that STS activity is present in both intact and lysed CRC cells, and this activity could be inhibited with STX64 (<bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>). Although the role of STS activity and estrogens in CRC is not yet defined, our results, combined with evidence showing increased STS expression as a poor prognostic indicator in CRC patients (<xref ref-type="bibr" rid="B32">Sato et al., 2009</xref>), suggests STX64 as a potential therapeutic option for this disease. Indeed, STX64 has shown significant promise in hormone-dependent breast cancer patients (<xref ref-type="bibr" rid="B35">Stanway et al., 2006</xref>, <xref ref-type="bibr" rid="B34">2007</xref>) with limited adverse events (<xref ref-type="bibr" rid="B35">Stanway et al., 2006</xref>). Further Phase II trials of STX64 are currently ongoing in patients with hormone-dependent breast cancer.</p>
<p>Cell protein (from cell lysates) exhibited significantly greater STS activity compared to intact cells suggesting E<sub>1</sub>S cell membrane transport as the limiting factor in estrogen hydrolysis. Thus, OATP expression patterns in CRC may be a key regulator of E<sub>1</sub>S transport and subsequent estrogen action. Our results demonstrate OATP4A1, followed by OATP2B1, as the most abundantly expressed E<sub>1</sub>S transporters in CRC cell lines (<bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). OATP4A1 is up-regulated and hypomethylated in CRC compared to normal colon tissue (<xref ref-type="bibr" rid="B28">Rawluszko-Wieczorek et al., 2015</xref>), suggesting its importance in disease progression, and implying that E<sub>1</sub>S uptake through this transporter may influence tumor proliferation. Furthermore, OATP3A1 is down-regulated in CRC (<xref ref-type="bibr" rid="B28">Rawluszko-Wieczorek et al., 2015</xref>), and reflected in our results as low expression of this transporter is evident in all four cell lines. OATP1B3 correlates to the Gleason score as a marker of CRC dedifferentiation: higher OATP1B3 expression in the colon is associated with earlier tumor stage and improved tumor differentiation (<xref ref-type="bibr" rid="B24">Pressler et al., 2011</xref>). We demonstrate low OATP1B3 expression in our cell lines, supporting a role for this transporter in early tumor stage as all four cell lines examined were derived from latter-stage tumors.</p>
<p>Once transported, E<sub>1</sub>S requires hydrolysis to form E<sub>1</sub>, and subsequently E<sub>2</sub> via 17&#x03B2;-hydroxysteroid dehydrogenase activity. However, controversy surrounds how estrogens act in CRC. Evidence suggests ER&#x03B1; is either lowly expressed (<xref ref-type="bibr" rid="B3">Cavallini et al., 2002</xref>) or not present (<xref ref-type="bibr" rid="B37">Witte et al., 2001</xref>), and ER&#x03B2; is down-regulated during CRC development from colon adenomas (<xref ref-type="bibr" rid="B14">Konstantinopoulos et al., 2003</xref>). Thus, we determined ER status in four CRC cell lines, showing that Caco2 and Colo205 cells have some ER&#x03B1; immunoreactivity (<bold>Figure <xref ref-type="fig" rid="F7">7</xref></bold>). None of the cell lines expressed ER&#x03B2;. As they did not express either ER&#x03B1; or ER&#x03B2;, we selected HCT116 and HT29 cells and determined that they expressed GPER. As ER&#x03B1; and ER&#x03B2; are not present in CRC, this suggests that estrogens may primarily act through GPER in CRC. Indeed, estrogen binding to GPER increases colonic transit time (<xref ref-type="bibr" rid="B16">Li et al., 2016</xref>) and is associated with pain severity in irritable bowel disease (<xref ref-type="bibr" rid="B27">Qin et al., 2014</xref>). However, this is the first report of GPER stimulation having a functional molecular consequence in STS activity.</p>
<p>Intriguingly, E<sub>2</sub> and G1, a specific GPER agonist, increased STS activity in HCT116 cell lines (<bold>Figure <xref ref-type="fig" rid="F7">7</xref></bold>), suggesting a potential novel positive estrogen feedback loop is present within CRC. In theory, greater STS activity should result in increased local E<sub>1</sub> and E<sub>2</sub> synthesis. Little is known about the regulation of STS activity. STS can undergo various post-translational modifications resulting in greater activity (<xref ref-type="bibr" rid="B36">Stengel et al., 2008</xref>), and this effect may be NF-&#x03BA;B regulated (<xref ref-type="bibr" rid="B13">Jiang et al., 2016</xref>). However, there are no other reports that estrogen availability impacts STS activity. In breast cancer, GPER stimulation by tamoxifen does elevate the expression of aromatase (<xref ref-type="bibr" rid="B2">Catalano et al., 2014</xref>), the enzyme involved in estrogen synthesis from androgen pre-cursors. It is with some interest then to see that tamoxifen also increased STS activity in HCT116 cell lines. As a selective ER modulator, tamoxifen is a first line therapy against hormone-dependent breast cancer. However, it has recently been shown that tamoxifen may act as a GPER agonist in tamoxifen-resistant tumors (<xref ref-type="bibr" rid="B19">Mo et al., 2013</xref>). Thus, tamoxifen-induced increase of STS activity, and therefore increasing local estrogen availability, in CRC and potentially other malignancies may represent a novel GPER-stimulated pathway regulating STS action. It will be of importance to further examine whether tamoxifen and fulvestrant induce STS activity via GPER stimulation, as this may represent a novel route for tamoxifen and fulvestrant resistance.</p>
</sec>
<sec><title>Conclusion</title>
<p>We have demonstrated here that CRC cell lines can transport E<sub>1</sub>S and have sufficient STS activity to liberate E<sub>1</sub>. STS activity is possibly regulated by local estrogen availability through GPER stimulation, and this represents a novel positive estrogen feedback loop within CRC. These results have direct consequences for HRT therapy, suggesting that HRT may increase STS activity in the colon leading to potentially undesired effects through GPER action.</p>
</sec>
<sec><title>Author Contributions</title>
<p>LG performed qRT-PCR and analysis on cell lines and wrote the manuscript, AG and VT performed STS activity assays, MH performed qRT-PCR analysis and ran the E1S uptake studies, A-MH performed qRT-PCR on cell lines, AA, performed immunoblotting, PF performed E1S uptake studies, STS activity assays, analyzed data, and wrote the manuscript.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>This work was supported by the Society for Endocrinology (UK) Early Careers Grant given to PF, and by a MRC Ph.D. stipend awarded to LG.</p>
</ack>
<sec sec-type="supplementary material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fphar.2017.00103/full#supplementary-material">http://journal.frontiersin.org/article/10.3389/fphar.2017.00103/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.TIF" id="SM1" mimetype="image/tif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleasby</surname> <given-names>K.</given-names></name> <name><surname>Castle</surname> <given-names>J. C.</given-names></name> <name><surname>Roberts</surname> <given-names>C. J.</given-names></name> <name><surname>Cheng</surname> <given-names>C.</given-names></name> <name><surname>Bailey</surname> <given-names>W. J.</given-names></name> <name><surname>Sina</surname> <given-names>J. F.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.</article-title> <source><italic>Xenobiotica</italic></source> <volume>36</volume> <fpage>963</fpage>&#x2013;<lpage>988</lpage>. <pub-id pub-id-type="doi">10.1080/00498250600861751</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Catalano</surname> <given-names>S.</given-names></name> <name><surname>Giordano</surname> <given-names>C.</given-names></name> <name><surname>Panza</surname> <given-names>S.</given-names></name> <name><surname>Chemi</surname> <given-names>F.</given-names></name> <name><surname>Bonofiglio</surname> <given-names>D.</given-names></name> <name><surname>Lanzino</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.</article-title> <source><italic>Breast Cancer Res. Treat.</italic></source> <volume>146</volume> <fpage>273</fpage>&#x2013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-014-3017-4</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavallini</surname> <given-names>A.</given-names></name> <name><surname>Messa</surname> <given-names>C.</given-names></name> <name><surname>Pricci</surname> <given-names>M.</given-names></name> <name><surname>Caruso</surname> <given-names>M. L.</given-names></name> <name><surname>Barone</surname> <given-names>M.</given-names></name> <name><surname>Di Leo</surname> <given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer.</article-title> <source><italic>Dig. Dis. Sci.</italic></source> <volume>47</volume> <fpage>2720</fpage>&#x2013;<lpage>2728</lpage>. <pub-id pub-id-type="doi">10.1023/A:1021053105096</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chlebowski</surname> <given-names>R. T.</given-names></name> <name><surname>Wactawski-Wende</surname> <given-names>J.</given-names></name> <name><surname>Ritenbaugh</surname> <given-names>C.</given-names></name> <name><surname>Hubbell</surname> <given-names>F. A.</given-names></name> <name><surname>Ascensao</surname> <given-names>J.</given-names></name> <name><surname>Rodabough</surname> <given-names>R. J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Estrogen plus progestin and colorectal cancer in postmenopausal women.</article-title> <source><italic>N. Engl. J. Med.</italic></source> <volume>350</volume> <fpage>991</fpage>&#x2013;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa032071350/10/991</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname> <given-names>M. K.</given-names></name> <name><surname>Burai</surname> <given-names>R.</given-names></name> <name><surname>Ramesh</surname> <given-names>C.</given-names></name> <name><surname>Petrie</surname> <given-names>W. K.</given-names></name> <name><surname>Alcon</surname> <given-names>S. N.</given-names></name> <name><surname>Nayak</surname> <given-names>T. K.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>In vivo effects of a GPR30 antagonist.</article-title> <source><italic>Nat. Chem. Biol.</italic></source> <volume>5</volume> <fpage>421</fpage>&#x2013;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.168nchembio.168</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Domenico</surname> <given-names>M.</given-names></name> <name><surname>Castoria</surname> <given-names>G.</given-names></name> <name><surname>Bilancio</surname> <given-names>A.</given-names></name> <name><surname>Migliaccio</surname> <given-names>A.</given-names></name> <name><surname>Auricchio</surname> <given-names>F.</given-names></name></person-group> (<year>1996</year>). <article-title>Estradiol activation of human colon carcinoma-derived Caco-2 cell growth.</article-title> <source><italic>Cancer Res.</italic></source> <volume>56</volume> <fpage>4516</fpage>&#x2013;<lpage>4521</lpage>.</citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farquhar</surname> <given-names>C. M.</given-names></name> <name><surname>Marjoribanks</surname> <given-names>J.</given-names></name> <name><surname>Lethaby</surname> <given-names>A.</given-names></name> <name><surname>Lamberts</surname> <given-names>Q.</given-names></name> <name><surname>Suckling</surname> <given-names>J. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Long term hormone therapy for perimenopausal and postmenopausal women.</article-title> <source><italic>Cochrane Database Syst. Rev.</italic></source> <volume>3</volume>:<issue>CD004143</issue>. <pub-id pub-id-type="doi">10.1002/14651858.CD004143.pub2</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>P. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Oestrogen and colorectal cancer: mechanisms and controversies.</article-title> <source><italic>Int. J. Colorectal. Dis.</italic></source> <volume>28</volume> <fpage>737</fpage>&#x2013;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1007/s00384-012-1628-y</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>P. A.</given-names></name> <name><surname>Chander</surname> <given-names>S. K.</given-names></name> <name><surname>Parsons</surname> <given-names>M. F.</given-names></name> <name><surname>Newman</surname> <given-names>S. P.</given-names></name> <name><surname>Woo</surname> <given-names>L. W.</given-names></name> <name><surname>Potter</surname> <given-names>B. V.</given-names></name><etal/></person-group> (<year>2008a</year>). <article-title>Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.</article-title> <source><italic>Breast Cancer Res. Treat.</italic></source> <volume>111</volume> <fpage>129</fpage>&#x2013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-007-9769-3</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>P. A.</given-names></name> <name><surname>Newman</surname> <given-names>S. P.</given-names></name> <name><surname>Chander</surname> <given-names>S. K.</given-names></name> <name><surname>Stengel</surname> <given-names>C.</given-names></name> <name><surname>Jhalli</surname> <given-names>R.</given-names></name> <name><surname>Woo</surname> <given-names>L. L.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.</article-title> <source><italic>Clin. Cancer Res.</italic></source> <volume>12</volume> <fpage>5543</fpage>&#x2013;<lpage>5549</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0632</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>P. A.</given-names></name> <name><surname>Woo</surname> <given-names>L. W.</given-names></name> <name><surname>Potter</surname> <given-names>B. V.</given-names></name> <name><surname>Reed</surname> <given-names>M. J.</given-names></name> <name><surname>Purohit</surname> <given-names>A.</given-names></name></person-group> (<year>2008b</year>). <article-title>The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.</article-title> <source><italic>Endocrinology</italic></source> <volume>149</volume> <fpage>4035</fpage>&#x2013;<lpage>4042</lpage>. <pub-id pub-id-type="doi">10.1210/en.2008-0223en.2008-0223</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennessy</surname> <given-names>B. A.</given-names></name> <name><surname>Harvey</surname> <given-names>B. J.</given-names></name> <name><surname>Healy</surname> <given-names>V.</given-names></name></person-group> (<year>2005</year>). <article-title>17beta-Estradiol rapidly stimulates c-fos expression via the MAPK pathway in T84 cells.</article-title> <source><italic>Mol. Cell. Endocrinol.</italic></source> <volume>229</volume> <fpage>39</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2004.10.001</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>M.</given-names></name> <name><surname>Klein</surname> <given-names>M.</given-names></name> <name><surname>Zanger</surname> <given-names>U. M.</given-names></name> <name><surname>Mohammad</surname> <given-names>M. K.</given-names></name> <name><surname>Cave</surname> <given-names>M. C.</given-names></name> <name><surname>Gaikwad</surname> <given-names>N. W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Inflammatory regulation of steroid sulfatase: a novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.</article-title> <source><italic>J. Hepatol.</italic></source> <volume>64</volume> <fpage>44</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2015.07.022S0168-8278(15)00513-9</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konstantinopoulos</surname> <given-names>P. A.</given-names></name> <name><surname>Kominea</surname> <given-names>A.</given-names></name> <name><surname>Vandoros</surname> <given-names>G.</given-names></name> <name><surname>Sykiotis</surname> <given-names>G. P.</given-names></name> <name><surname>Andricopoulos</surname> <given-names>P.</given-names></name> <name><surname>Varakis</surname> <given-names>I.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour&#x2019;s dedifferentiation.</article-title> <source><italic>Eur. J. Cancer</italic></source> <volume>39</volume> <fpage>1251</fpage>&#x2013;<lpage>1258</lpage>. <pub-id pub-id-type="doi">10.1016/S0959-8049(03)00239-9</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lepine</surname> <given-names>J.</given-names></name> <name><surname>Audet-Walsh</surname> <given-names>E.</given-names></name> <name><surname>Gregoire</surname> <given-names>J.</given-names></name> <name><surname>Tetu</surname> <given-names>B.</given-names></name> <name><surname>Plante</surname> <given-names>M.</given-names></name> <name><surname>Menard</surname> <given-names>V.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways.</article-title> <source><italic>J. Clin. Endocrinol. Metab.</italic></source> <volume>95</volume> <fpage>2689</fpage>&#x2013;<lpage>2698</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-2648jc.2010-2648</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Jiang</surname> <given-names>F.</given-names></name> <name><surname>Jiang</surname> <given-names>Z.</given-names></name> <name><surname>Liu</surname> <given-names>C.</given-names></name> <name><surname>Li</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>G protein-coupled estrogen receptor is involved in modulating colonic motor function via nitric oxide release in C57BL/6 female mice.</article-title> <source><italic>Neurogastroenterol. Motil.</italic></source> <volume>28</volume> <fpage>432</fpage>&#x2013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1111/nmo.12743</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Messa</surname> <given-names>C.</given-names></name> <name><surname>Notarnicola</surname> <given-names>M.</given-names></name> <name><surname>Russo</surname> <given-names>F.</given-names></name> <name><surname>Cavallini</surname> <given-names>A.</given-names></name> <name><surname>Pallottini</surname> <given-names>V.</given-names></name> <name><surname>Trentalance</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.</article-title> <source><italic>Scand. J. Gastroenterol.</italic></source> <volume>40</volume> <fpage>1454</fpage>&#x2013;<lpage>1461</lpage>. <pub-id pub-id-type="doi">10.1080/00365520510024007</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mikkaichi</surname> <given-names>T.</given-names></name> <name><surname>Suzuki</surname> <given-names>T.</given-names></name> <name><surname>Tanemoto</surname> <given-names>M.</given-names></name> <name><surname>Ito</surname> <given-names>S.</given-names></name> <name><surname>Abe</surname> <given-names>T.</given-names></name></person-group> (<year>2004</year>). <article-title>The organic anion transporter (OATP) family.</article-title> <source><italic>Drug Metab. Pharmacokinet.</italic></source> <volume>19</volume> <fpage>171</fpage>&#x2013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.19.171</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname> <given-names>Z.</given-names></name> <name><surname>Liu</surname> <given-names>M.</given-names></name> <name><surname>Yang</surname> <given-names>F.</given-names></name> <name><surname>Luo</surname> <given-names>H.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Tu</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.</article-title> <source><italic>Breast Cancer Res.</italic></source> <volume>15</volume> <issue>R114</issue>. <pub-id pub-id-type="doi">10.1186/bcr3581bcr3581</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname> <given-names>J. W.</given-names></name> <name><surname>Gilligan</surname> <given-names>L. C.</given-names></name> <name><surname>Idkowiak</surname> <given-names>J.</given-names></name> <name><surname>Arlt</surname> <given-names>W.</given-names></name> <name><surname>Foster</surname> <given-names>P. A.</given-names></name></person-group> (<year>2015</year>). <article-title>The regulation of steroid action by sulfation and desulfation.</article-title> <source><italic>Endocr. Rev.</italic></source> <volume>36</volume> <fpage>526</fpage>&#x2013;<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1210/er.2015-1036</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname> <given-names>Y.</given-names></name> <name><surname>Suzuki</surname> <given-names>T.</given-names></name> <name><surname>Fukuda</surname> <given-names>T.</given-names></name> <name><surname>Ito</surname> <given-names>A.</given-names></name> <name><surname>Endo</surname> <given-names>M.</given-names></name> <name><surname>Moriya</surname> <given-names>T.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Steroid sulfatase and estrogen sulfotransferase in human prostate cancer.</article-title> <source><italic>Prostate</italic></source> <volume>66</volume> <fpage>1005</fpage>&#x2013;<lpage>1012</lpage>. <pub-id pub-id-type="doi">10.1002/pros.20426</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasqualini</surname> <given-names>J. R.</given-names></name> <name><surname>Chetrite</surname> <given-names>G.</given-names></name> <name><surname>Blacker</surname> <given-names>C.</given-names></name> <name><surname>Feinstein</surname> <given-names>M. C.</given-names></name> <name><surname>Delalonde</surname> <given-names>L.</given-names></name> <name><surname>Talbi</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.</article-title> <source><italic>J. Clin. Endocrinol. Metab.</italic></source> <volume>81</volume> <fpage>1460</fpage>&#x2013;<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1210/jcem.81.4.8636351</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pizzagalli</surname> <given-names>F.</given-names></name> <name><surname>Hagenbuch</surname> <given-names>B.</given-names></name> <name><surname>Stieger</surname> <given-names>B.</given-names></name> <name><surname>Klenk</surname> <given-names>U.</given-names></name> <name><surname>Folkers</surname> <given-names>G.</given-names></name> <name><surname>Meier</surname> <given-names>P. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Identification of a novel human organic anion transporter polypeptide as a high affinity thyroxine transporter.</article-title> <source><italic>Mol. Endocrinol.</italic></source> <volume>16</volume> <fpage>2283</fpage>&#x2013;<lpage>2296</lpage>. <pub-id pub-id-type="doi">10.1210/me.2001-0309</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pressler</surname> <given-names>H.</given-names></name> <name><surname>Sissung</surname> <given-names>T. M.</given-names></name> <name><surname>Venzon</surname> <given-names>D.</given-names></name> <name><surname>Price</surname> <given-names>D. K.</given-names></name> <name><surname>Figg</surname> <given-names>W. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Expression of OATP family members in hormone-related cancers: potential markers of progression.</article-title> <source><italic>PLoS ONE</italic></source> <volume>6</volume> <issue>e20372</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0020372PONE-D-11-01633</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prossnitz</surname> <given-names>E. R.</given-names></name> <name><surname>Barton</surname> <given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Estrogen biology: new insights into GPER function and clinical opportunities.</article-title> <source><italic>Mol. Cell. Endocrinol.</italic></source> <volume>389</volume> <fpage>71</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2014.02.002S0303-7207(14)00039-2</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname> <given-names>A.</given-names></name> <name><surname>Froome</surname> <given-names>V. A.</given-names></name> <name><surname>Wang</surname> <given-names>D. Y.</given-names></name> <name><surname>Potter</surname> <given-names>B. V.</given-names></name> <name><surname>Reed</surname> <given-names>M. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate.</article-title> <source><italic>J. Steroid Biochem. Mol. Biol.</italic></source> <volume>62</volume> <fpage>45</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-0760(97)00018-6</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname> <given-names>B.</given-names></name> <name><surname>Dong</surname> <given-names>L.</given-names></name> <name><surname>Guo</surname> <given-names>X.</given-names></name> <name><surname>Jiang</surname> <given-names>J.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significance.</article-title> <source><italic>Int. J. Clin. Exp. Pathol.</italic></source> <volume>7</volume> <fpage>2238</fpage>&#x2013;<lpage>2246</lpage>.</citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rawluszko-Wieczorek</surname> <given-names>A. A.</given-names></name> <name><surname>Horst</surname> <given-names>N.</given-names></name> <name><surname>Horbacka</surname> <given-names>K.</given-names></name> <name><surname>Bandura</surname> <given-names>A. S.</given-names></name> <name><surname>Swiderska</surname> <given-names>M.</given-names></name> <name><surname>Krokowicz</surname> <given-names>P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Effect of DNA methylation profile on OATP3A1 and OATP4A1 transcript levels in colorectal cancer.</article-title> <source><italic>Biomed. Pharmacother.</italic></source> <volume>74</volume> <fpage>233</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2015.08.026S0753-3322(15)00211-5</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname> <given-names>X.</given-names></name> <name><surname>Wu</surname> <given-names>X.</given-names></name> <name><surname>Hillier</surname> <given-names>S. G.</given-names></name> <name><surname>Fegan</surname> <given-names>K. S.</given-names></name> <name><surname>Critchley</surname> <given-names>H. O.</given-names></name> <name><surname>Mason</surname> <given-names>J. I.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy.</article-title> <source><italic>J. Steroid Biochem. Mol. Biol.</italic></source> <volume>150</volume> <fpage>54</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.03.010S0960-0760(15)00095-3</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname> <given-names>M.</given-names></name> <name><surname>Obaidat</surname> <given-names>A.</given-names></name> <name><surname>Hagenbuch</surname> <given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.</article-title> <source><italic>Br. J. Pharmacol.</italic></source> <volume>165</volume> <fpage>1260</fpage>&#x2013;<lpage>1287</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01724.x</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santolla</surname> <given-names>M. F.</given-names></name> <name><surname>Lappano</surname> <given-names>R.</given-names></name> <name><surname>De Marco</surname> <given-names>P.</given-names></name> <name><surname>Pupo</surname> <given-names>M.</given-names></name> <name><surname>Vivacqua</surname> <given-names>A.</given-names></name> <name><surname>Sisci</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17beta-estradiol in cancer cells and cancer-associated fibroblasts.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>287</volume> <fpage>43234</fpage>&#x2013;<lpage>43245</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.417303M112.417303</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>R.</given-names></name> <name><surname>Suzuki</surname> <given-names>T.</given-names></name> <name><surname>Katayose</surname> <given-names>Y.</given-names></name> <name><surname>Miura</surname> <given-names>K.</given-names></name> <name><surname>Shiiba</surname> <given-names>K.</given-names></name> <name><surname>Tateno</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors.</article-title> <source><italic>Cancer Res.</italic></source> <volume>69</volume> <fpage>914</fpage>&#x2013;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-09060008-5472.CAN-08-0906</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x00F8;rby</surname> <given-names>L. A.</given-names></name> <name><surname>Anderson</surname> <given-names>S. N.</given-names></name> <name><surname>Bukholm</surname> <given-names>I. R.</given-names></name> <name><surname>Jacobsen</surname> <given-names>M. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Evaluation of suitable reference genes for normalization of real-time reverse transcription PCR analysis in colon cancer.</article-title> <source><italic>J. Exp. Clin. Cancer Res.</italic></source> <volume>29</volume>:<issue>144</issue>. <pub-id pub-id-type="doi">10.1186/1756-9966-29-144</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stanway</surname> <given-names>S. J.</given-names></name> <name><surname>Delavault</surname> <given-names>P.</given-names></name> <name><surname>Purohit</surname> <given-names>A.</given-names></name> <name><surname>Woo</surname> <given-names>L. W.</given-names></name> <name><surname>Thurieau</surname> <given-names>C.</given-names></name> <name><surname>Potter</surname> <given-names>B. V.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Steroid sulfatase: a new target for the endocrine therapy of breast cancer.</article-title> <source><italic>Oncologist</italic></source> <volume>12</volume> <fpage>370</fpage>&#x2013;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.12-4-370</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stanway</surname> <given-names>S. J.</given-names></name> <name><surname>Purohit</surname> <given-names>A.</given-names></name> <name><surname>Woo</surname> <given-names>L. W.</given-names></name> <name><surname>Sufi</surname> <given-names>S.</given-names></name> <name><surname>Vigushin</surname> <given-names>D.</given-names></name> <name><surname>Ward</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.</article-title> <source><italic>Clin. Cancer Res.</italic></source> <volume>12</volume> <fpage>1585</fpage>&#x2013;<lpage>1592</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1996</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stengel</surname> <given-names>C.</given-names></name> <name><surname>Newman</surname> <given-names>S. P.</given-names></name> <name><surname>Day</surname> <given-names>J. M.</given-names></name> <name><surname>Tutill</surname> <given-names>H. J.</given-names></name> <name><surname>Reed</surname> <given-names>M. J.</given-names></name> <name><surname>Purohit</surname> <given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Effects of mutations and glycosylations on STS activity: a site-directed mutagenesis study.</article-title> <source><italic>Mol. Cell. Endocrinol.</italic></source> <volume>283</volume> <fpage>76</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2007.11.012S0303-7207(07)00430-3</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname> <given-names>D.</given-names></name> <name><surname>Chirala</surname> <given-names>M.</given-names></name> <name><surname>Younes</surname> <given-names>A.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Younes</surname> <given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Estrogen receptor beta is expressed in human colorectal adenocarcinoma.</article-title> <source><italic>Hum. Pathol.</italic></source> <volume>32</volume> <fpage>940</fpage>&#x2013;<lpage>944</lpage>. <pub-id pub-id-type="doi">10.1053/hupa.2001.27117</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaichuk</surname> <given-names>T.</given-names></name> <name><surname>Ivancic</surname> <given-names>D.</given-names></name> <name><surname>Scholtens</surname> <given-names>D.</given-names></name> <name><surname>Schiller</surname> <given-names>C.</given-names></name> <name><surname>Khan</surname> <given-names>S. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Tissue-specific transcripts of human steroid sulfatase are under control of estrogen signaling pathways in breast carcinoma.</article-title> <source><italic>J. Steroid Biochem. Mol. Biol.</italic></source> <volume>105</volume> <fpage>76</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2006.12.101</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="fn01"><label>1</label><p><ext-link ext-link-type="uri" xlink:href="https://discover.nci.nih.gov/cellminer/">https://discover.nci.nih.gov/cellminer/</ext-link></p></fn>
</fn-group>
<glossary>
<title>Abbreviations</title>
<def-list id="DL1">
<def-item>
<term>BPS</term>
<def>
<p>bromsulphthalein</p>
</def>
</def-item>
<def-item>
<term>CRC</term>
<def>
<p>colorectal cancer</p>
</def>
</def-item>
<def-item>
<term>E<sub>1</sub></term>
<def>
<p>estrone</p>
</def>
</def-item>
<def-item>
<term>E<sub>2</sub></term>
<def>
<p>estradiol</p>
</def>
</def-item>
<def-item>
<term>E<sub>1</sub>S</term>
<def>
<p>estrone sulfate</p>
</def>
</def-item>
<def-item>
<term>ER</term>
<def>
<p>estrogen receptor</p>
</def>
</def-item>
<def-item>
<term>FBS</term>
<def>
<p>fetal bovine serum</p>
</def>
</def-item>
<def-item>
<term>GPER</term>
<def>
<p>G-protein coupled estrogen receptor</p>
</def>
</def-item>
<def-item>
<term>HRT</term>
<def>
<p>hormone replacement therapy</p>
</def>
</def-item>
<def-item>
<term>OATP</term>
<def>
<p>organic anion transporter polypeptides</p>
</def>
</def-item>
<def-item>
<term>sFBS</term>
<def>
<p>charcoal-stripped fetal bovine serum</p>
</def>
</def-item>
<def-item>
<term>SLCO</term>
<def>
<p>solute carrier organic transporter family</p>
</def>
</def-item>
<def-item>
<term>STS</term>
<def>
<p>steroid sulfatase</p>
</def>
</def-item>
<def-item>
<term>SULT</term>
<def>
<p>sulfotransferase</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>